21 January 2020 - Scotland receives superb value from the latest medicines and vaccines thanks to robust measures which ensure NHS Scotland uses treatments that are both cost and clinically effective.

Companies can’t just pick a price for a medicine and there are controls in place to give NHS Scotland predictability on its medicines budget.

The Voluntary Pricing and Access Scheme, or ‘VPAS’, is a five-year agreement between the pharmaceutical industry, the Government and the NHS which controls spending on new medicine.

Read ABPI press release